InvestSMART

Imugene Limited (ASX: IMU) - Announcements

Current share price for IMU : $0.083 0.001 (1.22%)+

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$41 HER-Vaxx peptides demonstrate high level of activity 1 Dec 2014 10:06AM $0.010 $0.083 risen by 730%
$41 Imugene to divest Linguet drug delivery technology 28 Nov 2014 9:44AM $0.010 $0.083 risen by 730%
$41 Capital raising for clinical development of HER-Vaxx 5 Nov 2014 9:24AM $0.011 $0.083 risen by 654.55%
$41 Trading Halt 3 Nov 2014 9:16AM $0.011 $0.083 risen by 654.55%
$41 Appendix 4C - quarterly 31 Oct 2014 5:21PM $0.011 $0.083 risen by 654.55%
$41 Imugene HER-Vaxx patent granted in US 8 Oct 2014 9:42AM $0.013 $0.083 risen by 538.46%
$41 Swiss Drug Manufacturer to Speed Her-Vaxx Development 15 Sep 2014 9:02AM $0.016 $0.083 risen by 418.75%
$41 Research Agreement with Medical University of Vienna 8 Sep 2014 9:11AM $0.015 $0.083 risen by 453.33%
$41 Appendix 4E and Annual Financial Report 28 Aug 2014 5:37PM $0.018 $0.083 risen by 361.11%
$41 Charles Walker appointed Imugene CEO 26 Aug 2014 9:06AM $0.017 $0.083 risen by 388.24%
$41 HER-Vaxx patent application receives US Notice of Allowance 29 Jul 2014 9:34AM $0.014 $0.083 risen by 492.86%
$41 Appendix 4C - quarterly 25 Jul 2014 10:30AM $0.016 $0.083 risen by 418.75%
$41 Mymetics Engaged to Manufacture HER-Vaxx 16 Jul 2014 9:28AM $0.015 $0.083 risen by 453.33%
$41 Imugene Commences Manufacture of its Gastric Cancer Vaccine 27 May 2014 12:12PM $0.011 $0.083 risen by 654.55%
$41 Appendix 4C - quarterly 23 Apr 2014 2:56PM $0.012 $0.083 risen by 591.67%
$41 Imugene Allowed Israel Patent for Cancer Vaccine 24 Mar 2014 9:08AM $0.014 $0.083 risen by 492.86%
$41 IMU Commences FDA IND Process for Gastric Cancer vaccine 17 Mar 2014 9:03AM $0.015 $0.083 risen by 453.33%
$41 Half Yearly Report and Accounts 27 Feb 2014 3:48PM $0.015 $0.083 risen by 453.33%
$41 Appendix 4C - quarterly 29 Jan 2014 2:34PM $0.019 $0.083 risen by 336.84%
$41 Imugene Secures Important Intellectual Property 19 Dec 2013 9:07AM $0.014 $0.083 risen by 492.86%
$41 Appendix 4C - quarterly 24 Oct 2013 4:22PM $0.018 $0.083 risen by 361.11%
$41 Capital Raising Complete 23 Oct 2013 9:41AM $0.015 $0.083 risen by 453.33%
$41 Imugene to acquire Biolife Science Qld Limited 23 Oct 2013 9:13AM $0.015 $0.083 risen by 453.33%
$41 Trading Halt 21 Oct 2013 9:32AM $0.012 $0.083 risen by 591.67%
$41 European patent for novel drug delivery technology 27 Sep 2013 11:05AM $0.008 $0.083 risen by 937.50%

1026 - 1050 of 1187 results

Page 42 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.